Pharmaceuticals, Biotechnology and Life Sciences
“These findings may help inform specialists treating patients with overactive bladder, that BOTOX is an effective and safe treatment option for patients not getting the relief from an anticholinergic.”
The Wolfson Institute of Preventive Medicine with the assistance of Premaitha Health plc , is launching an in-house antenatal reflex DNA screening service on 19 October 2015.
Medline Industries, Inc. announced that it will initiate a voluntary nationwide recall of lot # 45810 of Acetaminophen tablets, 500mg, uncoated compressed tablets to the consumer level.
Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. have announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications.
Novartis has announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer.
Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
Verona Pharma plc , the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).
Quantum Pharma Plc has announced that it had signed an exclusive agreement with Futura Medical plc the healthcare company which is focused on advanced transdermal technology, to manufacture and make available MED2002, Futura’s novel treatment for erectile dysfunction, as an unlicensed medicine (special) in the UK (the “Agreement”).
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) has expanded its in-house NIPT screening service by opening a dedicated laboratory which triples clinical capacity in response to demand for the IONA test from clinicians.
Johnson & Johnson has had sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third quarter of 2014.